INS and type 1 diabetes mellitus: Several considerations justify future clinical studies to investigate whether ABA supplementation could improve insulin action in T1D patients: together with insulin, plasma ABA is also undetectable or very low in T1D patients [11], suggesting that β-cells are the principal source of endogenous ABA in humans (in rodents, BAT is also a major source of ABA [24]).